July 25, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for March 18, 2008 Subscribe to this News Feed  
 

Experimental Treatments for Age-Related Macular Degeneration

Download this press release as an Adobe PDF document.

Age-Related Macular Degeneration is the #1 cause of blindness in the US. Johns Hopkins Vision Health Alerts reports on the use of human stem cells to enable the retina to repair itself.

NEW YOR, NY (PRWEB) March 18, 2008-- Johns Hopkins Vision Health Alerts recently reported on the promising new use of human stem cells to enable the retina to repair itself.

NEW TREATMENTS FOR MACULAR DEGENERATION
Several new treatments are under investigation that may help prevent vision loss in people with age-related macular degeneration.

Besides continuing development of treatments to prevent new blood vessel growth, as well as leakage from blood vessels in the eye, researchers are also studying drugs known as angiostatic corticosteroids (such as anecortave acetate, tramcinolone, and flucinolone), sometimes in conjunction with other treatments such as photodynamic therapy.

PROMISING NEW TREATMENT ON THE HORIZON
Human retinas damaged by diseases, such as age-related macular degeneration and diabetic retinopathy, are unable to repair themselves.

But now in a report from the National Academy of Sciences (Volume 103, page 12769), researchers at the University of Washington and elsewhere suggest that the regeneration of damaged cells in the retina may someday be possible. Their optimism is based on successful treatment of diseased retinas in mice using human stem cells.

USING STEMS CELLS: THE STUDY RESULTS SO FAR
The University of Washington scientists first grew human embryonic stem cells (from a cell line approved in the United States) in a lab, then added growth factors -- proteins that enable cell growth -- central to the development of both human and mouse heads as well as a growth factor essential to a frog's sprouting of large eyes.

Within two weeks -- twice as fast as human cell development -- the embryonic cells became progenitor (forerunner) cells for retinal cells.

The scientists injected these into a damaged mouse retina, where they developed into cones (the retinal cells responsible for color), rods (the cells that allow night vision), and other cells.

The scientists' next step will be to measure the nerve reactions within the repaired mouse retinas to see if vision has improved.

THE BOTTOM LINE
If the research proceeds well, the researchers speculate that human tests using stem cells to repair retinas damaged by age-related macular degeneration might begin in two to three years.

For a free special report, The Johns Hopkins Guide to Age-Related Macular Degeneration, please visit: Johns Hopkins Guide to Age-Related Macular Degeneration

For the latest Vision Health Alerts, please visit:
Johns Hopkins Vision Health Alerts

For more information on the latest annual Johns Hopkins White Paper: Vision, please visit:
Johns Hopkins White Paper: Vision 2008

###

Trackback URL: http://www.prweb.com/pingpr.php/Q291cC1NYWduLUhhbGYtQ3Jhcy1Ib3JyLVplcm8=


Other Releases by this Member
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
JOAN MULLALLY
Johns Hopkins Health Alerts
917-640-4362
Email us Here

There are no multimedia files attached to this release. If this is your release you may add images or other multimedia files through your login.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright